Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation
© Mak et al.; licensee BioMed Central Ltd. 2014
Received: 3 January 2014
Accepted: 1 August 2014
Published: 8 August 2014
Prostate cancer is a commonly diagnosed and treated malignancy, although it rarely presents with cutaneous metastases. In this case presentation, we describe the diagnosis and treatment with radiotherapy of a patient who presented with cutaneous metastases on his chest wall secondary to prostate cancer.
In 2006, a 73-year-old Caucasian gentleman with metastatic castration resistant prostate cancer treated with mitoxantrone and prednisolone presented with cutaneous nodules on his chest wall. A punch biopsy diagnosed cutaneous metastases, with histological confirmation with positive staining for cytokeratin, PSA (prostate specific antigen) and PAP (prostatic acid phosphatise). Systemic treatment was ceased due to progressive disease; radiotherapy was used to treat these nodules with a durable clinical response. The patient died five months after initial diagnosis of cutaneous metastases.
In this report, a rare metastatic manifestation of a common malignancy is presented. Whilst dermal metastases carries a poor prognosis from reported literature, this is the first report of radiotherapy providing a durable clinical response with relief from bleeding and pain.
Prostate cancer is the most commonly diagnosed cancer in Australia, with an estimated incidence of 18,560 in 2012 . However, the skin is an uncommon site of metastasis and constitutes 5.3% of metastatic sites for all cancers . In prostate cancer, cutaneous metastasis is very rare with a published incidence of 0.36%  - when it occurs, it usually presents as nodules in the inguinal region and anterior thigh . Cutaneous metastases can also be inflammatory, fibrotic or sclerodermoid , and symptomatically, can be on a spectrum of being asymptomatic to being ulcerative and painful .
Metastasis to the chest wall is uncommon, although there is one case report published of cutaneous metastasis to the neck and upper chest . The mechanism of spread is not entirely understood – direct extension, lymphatic and haematogenous spread or combination of these, have all been proposed [3, 6, 8–10].
We report herin a patient with metastatic castration resistant prostate cancer, who presented with cutaneous nodules confirmed to be metastases from his prostate cancer. This was subsequently treated by radiotherapy, with a clinically durable response. It is of interest for the rarity of its presentation, and potential treatment with radiotherapy.
In 2006, a 73-year-old Caucasian man presented with nodular lesions on the left chest wall while receiving mitoxantrone and prednisolone for metastatic hormone refractory prostate cancer with skeletal metastases. At the time, mitoxantrone was the standard systemic chemotherapy for this condition, this gentleman was first diagnosed with prostate cancer 9 years previously. Past treatments included androgen deprivation, strontium, carboplatin–etoposide, radiotherapy to the chest wall for pain in the manubrium and sternum; and also with cisplatinum–phenoxidiol (as part of a phase 1 clinical trial). He initially responded well to mitoxantrone with a fall in the serum prostate specific antigen (PSA) and resolution of bone pain.
The PSA continued to rise, however, and further symptoms developed including fatigue, leg swelling and dyspnoea. A computed tomography (CT) scan revealed bilateral pleural effusions, the larger effusion on the left was drained. The cytology of the fluid revealed adenocarcinoma cells staining with anti-cytokeratin antibody CAM 5.2, PSA and PAP consistent with metastatic disease.The treated cutaneous lesions did not cause further problems but new lesions were found out of the field of radiotherapy treatment (Figure 4). He continued to decline and required a second pleurocentesis. At this time there were also changes on CT consistent with pulmonary lymphangitis, he subsequently died in hospital 2 weeks later.
In prostate cancer, dermal involvement generally presents late in the disease and is associated with poor prognosis [3, 6]. One review of literature estimates mean survival time from diagnosis of cutaneous metastasis at being 7 months . In this case, the patient had metastatic prostate cancer for 9.5 years in total and died 5 months from the initial diagnosis of the skin metastases. These occurred at failure of biochemical response to chemotherapy, and became more extensive and symptomatic as the PSA increased.
The mechanism of spread is uncertain – in our case, the finding of pleural effusions with cytology positive for prostate cancer cells in this case raises the possibility of a transmural infiltration of metastases in the chest wall. Histologically, there are multiple reported morphological patterns, and it typically shows immunohistochemistry positivity for PSA and PAP. However, expected morphology and staining may not be present in a poorly differentiated specimen [8, 11, 12].
This patient also had a significant and durable local response to radiotherapy. The symptoms of bleeding and pain completely subsided after treatment with 18 Gy in 3 fractions; although this did not lower serum PSA or stop systemic progression.
Treatment options for cutaneous metastases include local excision, intralesional chemotherapy  or radiotherapy. Our literature review revealed no published reports specifically for radiotherapy treatment for cutaneous metastases of prostate carcinoma. In this case, we report that radiotherapy can be a safe and effective treatment with a durable response in this rare metastatic presentation of a common tumour.
Written informed consent was obtained from the patient, prior to his death, for publication of this case report and accompanying images. Furthermore, written informed consent from the patient’s next-of-kin was also sought post mortem, and a copy of the written consent is available for review by the Editor-in-Chief of this journal.
There are no other parties relevant to be acknowledged for the preparation of this manuscript.
- Australian Institute of Health and Welfare & Australasian Association of Cancer Registries: Cancer series no. 74. Cat. no. CAN 70. Cancer in Australia: an overview 2012. 2012, Canberra: AIHWGoogle Scholar
- Krathen RA, Orengo IF, Rosen T: Cutaneous metastasis: a meta-analysis of data. South Med J. 2003, 96 (2): 164-167.PubMedView ArticleGoogle Scholar
- Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, Uzzo RG: Cutaneous metastases from genitourinary malignancies. Urology. 2004, 63 (6): 1021-1026.PubMedView ArticleGoogle Scholar
- Pique Duran E, Paradela A, Farina MC, Escalonilla P, Soriano ML, Olivares M, Sarasa JL, Martin L, Requena L: Cutaneous metastases from prostatic carcinoma. J Surg Oncol. 1996, 62 (2): 144-147.PubMedView ArticleGoogle Scholar
- Katske FA, Waisman J, Lupu AN: Cutaneous and subcutaneous metastases from carcinoma of prostate. Urology. 1982, 19 (4): 373-376.PubMedView ArticleGoogle Scholar
- Bailey C, Broadbent A: Cutaneous metastases of prostate cancer. J Palliat Med. 2007, 10 (4): 980-982.PubMedView ArticleGoogle Scholar
- Abrol N, Seth A, Chattergee P: Cutaneous metastasis of prostate carcinoma to neck and upper chest. Indian J Pathol Microbiol. 2011, 54 (2): 394-395.PubMedView ArticleGoogle Scholar
- Rattanasirivilai A, Kurban A, Lenzy Y, Yaar R: Cutaneous metastasis of prostatic adenocarcinoma: a cautionary tale. J Cutan Pathol. 2011, 38 (6): 521-524.PubMedView ArticleGoogle Scholar
- Wang SQ, Mecca PS, Myskowski PL, Slovin SF: Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature. J Cutan Pathol. 2008, 35 (7): 681-684.PubMedView ArticleGoogle Scholar
- Reddy S, Bang R, Contreras M: Telangiectatic cutaneous metastasis from carcinoma of the prostate. Br J Dermatol. 2007, 156 (3): 598-600.PubMedView ArticleGoogle Scholar
- Petcu E, Gonzalez-Serva A, Wright R, Slevin M, Brinzaniuc K: Prostate carcinoma metastatic to the skin as an extrammamary Paget’s disease. Diagn Pathol. 2012, 7 (1): 106-PubMedPubMed CentralView ArticleGoogle Scholar
- Varma M, Jasani B: Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005, 47 (1): 1-16.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.